117 related articles for article (PubMed ID: 37167897)
1. Textbook outcome as a composite outcome measure to compare hospital performances regarding cytoreductive surgery for ovarian cancer: A nationwide population-based study.
Algera MD; Slangen BFM; van Driel WJ; Wouters MWJM; Kruitwagen RFPM;
Gynecol Oncol; 2023 Jul; 174():89-97. PubMed ID: 37167897
[TBL] [Abstract][Full Text] [Related]
2. Case-mix adjustment to compare hospital performances regarding complications after cytoreductive surgery for ovarian cancer: a nationwide population-based study.
Algera MD; Baldewpersad Tewarie NMS; Driel WJV; van Ham MAPC; Slangen BFM; Kruitwagen RFPM; Wouters MWJM;
Int J Gynecol Cancer; 2023 Apr; 33(4):534-542. PubMed ID: 36581486
[TBL] [Abstract][Full Text] [Related]
3. Effect of surgical volume on short-term outcomes of cytoreductive surgery for advanced-stage ovarian cancer: A population-based study from the Dutch Gynecological Oncology Audit.
Algera MD; van Driel WJ; Slangen BFM; Wouters MWJM; Kruitwagen RFPM;
Gynecol Oncol; 2024 Apr; 186():144-153. PubMed ID: 38688188
[TBL] [Abstract][Full Text] [Related]
4. Oncologic outcomes after splenectomy during initial cytoreductive surgery in advanced epithelial ovarian cancer: a nationwide population-based cohort study.
Said SA; van der Aa MA; Veldmate G; de Hullu JA; van Altena AM
Acta Obstet Gynecol Scand; 2022 Jan; 101(1):56-67. PubMed ID: 34719790
[TBL] [Abstract][Full Text] [Related]
5. Survival and Surgical Approach among Women with Advanced Ovarian Cancer Treated with Neoadjuvant Chemotherapy.
Persenaire C; Pyrzak A; Barber EL
J Minim Invasive Gynecol; 2022 Mar; 29(3):375-384. PubMed ID: 34648931
[TBL] [Abstract][Full Text] [Related]
6. Interval debulking surgery is not worth the wait: a National Cancer Database study comparing primary cytoreductive surgery versus neoadjuvant chemotherapy.
Lyons YA; Reyes HD; McDonald ME; Newtson A; Devor E; Bender DP; Goodheart MJ; Gonzalez Bosquet J
Int J Gynecol Cancer; 2020 Jun; 30(6):845-852. PubMed ID: 32341114
[TBL] [Abstract][Full Text] [Related]
7. Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
Yao SE; Tripcony L; Sanday K; Robertson J; Perrin L; Chetty N; Land R; Garrett A; Obermair A; Nascimento M; Tang A; Jagasia N; Singh P; Nicklin J
Int J Gynecol Cancer; 2020 Dec; 30(12):1935-1942. PubMed ID: 33122245
[TBL] [Abstract][Full Text] [Related]
8. Incorporating robotic surgery into the management of ovarian cancer after neoadjuvant chemotherapy.
Abitbol J; Gotlieb W; Zeng Z; Ramanakumar A; Kessous R; Kogan L; Pare-Miron V; Rombaldi M; Salvador S; Kucukyazici B; Brin S; How J; Lau S
Int J Gynecol Cancer; 2019 Nov; 29(9):1341-1347. PubMed ID: 31601648
[TBL] [Abstract][Full Text] [Related]
9. Clinical validation and comparison of the Comprehensive Complication Index and Clavien-Dindo classification in predicting post-operative outcomes after cytoreductive surgery in advanced ovarian cancer.
Kengsakul M; Nieuwenhuyzen-de Boer GM; Udomkarnjananun S; Kerr SJ; van Doorn HC; van Beekhuizen HJ
Int J Gynecol Cancer; 2023 Feb; 33(2):263-270. PubMed ID: 36600504
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant Use of PlasmaJet Device During Cytoreductive Surgery for Advanced-Stage Ovarian Cancer: Results of the PlaComOv-study, a Randomized Controlled Trial in The Netherlands.
Nieuwenhuyzen-de Boer GM; Hofhuis W; Reesink-Peters N; Willemsen S; Boere IA; Schoots IG; Piek JMJ; Hofman LN; Beltman JJ; van Driel WJ; Werner HMJ; Baalbergen A; van Haaften-de Jong AMLD; Dorman M; Haans L; Nedelcu I; Ewing-Graham PC; van Beekhuizen HJ
Ann Surg Oncol; 2022 Aug; 29(8):4833-4843. PubMed ID: 35552938
[TBL] [Abstract][Full Text] [Related]
11. [Technical essentials and safety analysis of "rolling carpet" cytoreduction surgery in stage Ⅲc epithelial ovarian cancer].
Liu H; Shi Y; Zhang GN; Yu J; Xu SQ; Wang DF; Fan Y; Song SQ; Zhou FZ
Zhonghua Fu Chan Ke Za Zhi; 2020 Aug; 55(8):521-528. PubMed ID: 32854476
[No Abstract] [Full Text] [Related]
12. Textbook outcome after rectal cancer surgery as a composite measure for quality of care: A population-based study.
Warps AK; Detering R; Tollenaar RAEM; Tanis PJ; Dekker JWT;
Eur J Surg Oncol; 2021 Nov; 47(11):2821-2829. PubMed ID: 34120807
[TBL] [Abstract][Full Text] [Related]
13. Outcome of surgery in advanced ovarian cancer varies between geographical regions; opportunities for improvement in The Netherlands.
Timmermans M; Sonke GS; Slangen BFM; Baalbergen A; Bekkers RLM; Fons G; Gerestein CG; Kruse AJ; Roes EM; Zusterzeel PLM; Van de Vijver KK; Kruitwagen RFPM; van der Aa MA
Eur J Surg Oncol; 2019 Aug; 45(8):1425-1431. PubMed ID: 31027945
[TBL] [Abstract][Full Text] [Related]
14. Pattern of recurrence after interval cytoreductive surgery and HIPEC following neoadjuvant chemotherapy in primary advanced stage IIIC/IVA epithelial ovarian cancer.
Sinukumar S; Damodaran D; Ray M; Mehta S; Paul L; Bhatt A
Eur J Surg Oncol; 2021 Jun; 47(6):1427-1433. PubMed ID: 33509612
[TBL] [Abstract][Full Text] [Related]
15. Upfront cytoreductive surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer in Indian patients.
Ray MD; Deo SSV; Kumar L; Gaur MK
Future Oncol; 2021 Sep; 17(27):3607-3614. PubMed ID: 34263662
[TBL] [Abstract][Full Text] [Related]
16. Postoperative outcomes of primary and interval cytoreductive surgery for advanced ovarian cancer registered in the Dutch Gynecological Oncology Audit (DGOA).
Baldewpersad Tewarie NMS; van Driel WJ; van Ham M; Wouters MW; Kruitwagen R;
Gynecol Oncol; 2021 Aug; 162(2):331-338. PubMed ID: 34147284
[TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics and outcomes after bowel surgery and ostomy formation at the time of debulking surgery for advanced-stage epithelial ovarian carcinoma.
Gockley AA; Fiascone S; Hicks Courant K; Pepin K; Del Carmen M; Clark RM; Goldberg J; Horowitz N; Berkowitz R; Worley M
Int J Gynecol Cancer; 2019 Mar; 29(3):585-592. PubMed ID: 30833444
[TBL] [Abstract][Full Text] [Related]
18. Critical Analysis of Stage IV Epithelial Ovarian Cancer Patients after Treatment with Neoadjuvant Chemotherapy followed by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).
Munoz-Zuluaga CA; Sardi A; Sittig M; Gushchin V; King MC; Nieroda C; Lopez-Ramirez F; Diaz-Montes TP
Int J Surg Oncol; 2020; 2020():1467403. PubMed ID: 33381312
[TBL] [Abstract][Full Text] [Related]
19. Morbidity after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with carboplatin used for ovarian, tubal, and primary peritoneal cancer.
Mikkelsen MS; Christiansen T; Petersen LK; Blaakaer J; Iversen LH
J Surg Oncol; 2019 Sep; 120(3):550-557. PubMed ID: 31267569
[TBL] [Abstract][Full Text] [Related]
20. Pre-operative prediction of residual disease after interval cytoreduction for epithelial ovarian cancer using HE4.
Lof P; van de Vrie R; Korse CM; van Driel WJ; van Gent MDJM; Karlsen MA; Amant F; Lok CAR
Int J Gynecol Cancer; 2019 Oct; 29(8):1304-1310. PubMed ID: 31515411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
